Difference between revisions of "Buparlisib (BKM-120)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases Category:Drug index [[...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases | Orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases | ||
| + | |||
| + | ==Preliminary data== | ||
| + | ===[[Head and neck cancer]]=== | ||
| + | # Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017 Mar;18(3):323-335. Epub 2017 Jan 26. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30064-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28131786 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 01:40, 18 April 2017
Mechanism of action
Orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases
Preliminary data
Head and neck cancer
- Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017 Mar;18(3):323-335. Epub 2017 Jan 26. link to original article PubMed